FDA
-
-
-
-
-
-
-
MeiraGTx reports sustained benefits from gene therapy trial at 3 years
-
-
-
-
-
-
-
MeiraGTx receives FDA breakthrough therapy designation for xerostomia treatment
-
-
-
-
-
-
-
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
-
-
-
-
-
-
-
MeiraGTx Holdings plc (MGTX) Enters into a Strategic Collaboration with Hologen AI
-
-
-
-
-
-
-
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
-
-
-
-
-
-
-
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
-
-
-
-
-
-
-
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
-
326,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

